Virologic Suppression Can Be Maintained In Patients With HIV Receiving INSTI-Containing ART With Short-Course Rifapentine-Based Regimens For Latent TB Management

Infectious Disease Advisor (1/23, Nye) reports, “Virologic suppression can be maintained among patients with HIV infection receiving integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) in combination with short-course rifapentine-based regimens for latent tuberculosis (TB) management, according to study results published in Clinical Infectious Diseases.” In analysis, the study found the only factor “significantly associated with failure to maintain HIV virologic response (adjusted OR, 12.67; 95% CI, 2.92-54.98; P =.001)” was incarceration.